Prediabetes is a window of opportunity for preventive interventions. Part 2

Early disorders of carbohydrate metabolism, due to their high prevalence, are an urgent clinical problem. Many studies indicate a low awareness of primary care physicians about the criteria for diagnosis and approaches to the treatment of prediabetes. However, it is at the stage of prediabetes that changes in various organs and systems characteristic of hyperglycemia begin to form. Early diagnosis and initiation of therapy will improve the quality of life, prevent complications, delay or prevent the development of diabetes mellitus. The purpose of the review is to provide up–to-date data on the diagnosis and treatment of prediabetes. The criteria for disorders of carbohydrate metabolism were described in the 1970s–80s, but a universal approach to diagnosing prediabetes is still lacking. A number of contentious issues remain: whether this condition is truly a stage in the development of diabetes, which diagnostic method to choose, whether lifestyle modifications are sufficient or if drug therapy should be initiated, and which therapeutic method to select. A total of 37 articles were analyzed, including data from randomized controlled trials (RCTs) and 2024 guidelines. The modern physician’s toolkit includes the possibility of pharmacological prevention of type 2 diabetes mellitus using the drug Subetta. This biological agent is created based on affinity-purified antibodies to the C-terminal fragment of the insulin receptor β-subunit and to endothelial NO-synthase. It has a pleiotropic mechanism of action: it increases cell sensitivity to insulin, thereby providing the drug’s hypoglycemic effect. Further information is needed for physicians about various specialties, the risks of developing various organs and systems at the prediabetic stage, and the introduction of active screening and therapy methods.

1. Драпкина ОМ, Мокрышева НГ, Шестакова МВ, Лавренова ЕА и др. Диспансерное наблюдение пациентов с предиабетом врачом-терапевтом в первичном звене здравоохранения. М.: РОПНИЗ; 2024. 36 с. https://doi.org/10.15829/ROPNIZ-d100-2024.

2. Ramlo-Halsted BA, Edelman SV. The natural history of type 2 diabetes. Implications for clinical practice. Prim Care. 1999;26(4):771–789. https://doi.org/10.1016/s0095-4543(05)70130-5.

3. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28(12):1039–1057. https://doi.org/10.2337/diab.28.12.1039.

4. Bergman M, Abdul-Ghani M, DeFronzo RA, Manco M, Sesti G, Fiorentino TV et al. Review of methods for detecting glycemic disorders. Diabetes Res Clin Pract. 2020;165:108233. https://doi.org/10.1016/j.diabres.2020.108233.

5. Дедов ИИ, Шестакова МВ, Сухаревой ОЮ (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 12-й выпуск. М.; 2025. 248 c. Режим доступа: https://www.endocrincentr.ru/sites/default/files/all/specialists/algoritmy_specializirovannoy_medicinskoi_pomoschi_bolnym_sd_2025.pdf.

6. Guo F, Moellering DR, Garvey WT. Use of HbA1c for diagnoses of diabetes and prediabetes: comparison with diagnoses based on fasting and 2-hr glucose values and effects of gender, race, and age. Metab Syndr Relat Disord. 2014;12(5):258–268. https://doi.org/10.1089/met.2013.0128.

7. Gosmanov AR, Wan J. Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice. Am J Med Sci. 2014;348(3):191–194. https://doi.org/10.1097/MAJ.0000000000000223.

8. van ‘t Riet E, Alssema M, Rijkelijkhuizen JM, Kostense PJ, Nijpels G, Dekker JM. Relationship between A1C and glucose levels in the general Dutch population: the new Hoorn study. Diabetes Care. 2010;33(1):61–66. https://doi.org/10.2337/dc09-0677.

9. Bloomgarden ZT, Inzucchi SE, Karnieli E, Le Roith D. The proposed terminology ‘A(1c)-derived average glucose’ is inherently imprecise and should not be adopted. Diabetologia. 2008;51(7):1111–1114. https://doi.org/10.1007/s00125-008-1027-7.

10. Cohen RM, Snieder H, Lindsell CJ, Beyan H, Hawa MI, Blinko S et al. Evidence for independent heritability of the glycation gap (glycosylation gap) fraction of HbA1c in nondiabetic twins. Diabetes Care. 2006;29(8):1739–1743. https://doi.org/10.2337/dc06-0286.

11. Gallagher EJ, Le Roith D, Bloomgarden Z. Review of hemoglobin A(1c) in the management of diabetes. J Diabetes. 2009;1(1):9–17. https://doi.org/10.1111/j.1753-0407.2009.00009.x.

12. Fiorentino TV, Marini MA, Andreozzi F, Arturi F, Succurro E, Perticone M et al. One-Hour Postload Hyperglycemia Is a Stronger Predictor of Type 2 Diabetes Than Impaired Fasting Glucose. J Clin Endocrinol Metab. 2015;100(10):3744–3751. https://doi.org/10.1210/jc.2015-2573.

13. Fiorentino TV, Marini MA, Andreozzi F, Arturi F, Succurro E, Perticone M et al. One-Hour Postload Hyperglycemia: Implications for Prediction and Prevention of Type 2 Diabetes. J Clin Endocrinol Metab. 2018;103(9):3131–3143. https://doi.org/10.1210/jc.2018-00468.

14. Lizarzaburu-Robles JC, Herman WH, Garro-Mendiola A, Galdón Sanz-Pastor A, Lorenzo O. Prediabetes and Cardiometabolic Risk: The Need for Improved Diagnostic Strategies and Treatment to Prevent Diabetes and Cardiovascular Disease. Biomedicines. 2024;12(2):363. https://doi.org/10.3390/biomedicines12020363.

15. Shah VN, DuBose SN, Li Z, Beck RW, Peters AL, Weinstock RS et al. Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study. J Clin Endocrinol Metab. 2019;104(10):4356–4364. https://doi.org/10.1210/jc.2018-02763.

16. Monnier L, Colette C, Dejager S, Owens D. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care. 2013;36(12):4057–4062. https://doi.org/10.2337/dc12-2127.

17. Lee DY, Jung I, Park SY, Yu JH, Seo JA, Kim KJ et al. Attention to Innate Circadian Rhythm and the Impact of Its Disruption on Diabetes. Diabetes Metab J. 2024;48(1):37–52. https://doi.org/10.4093/dmj.2023.0193.

18. Friedman JG, Smith EP, Awasty SS, Behan M, Genco MT, Hempel H et al. Primary care diabetes assessment when HbA1c and other measures of glycemia disagree. Prim Care Diabetes. 2024;18(2):151–156. https://doi.org/10.1016/j.pcd.2023.12.005.

19. Umeno A, Fukui T, Hashimoto Y, Kataoka M, Hagihara Y, Nagai H et al. Early diagnosis of type 2 diabetes based on multiple biomarkers and noninvasive indices. J Clin Biochem Nutr. 2018;62(2):187–194. https://doi.org/10.3164/jcbn.17-81.

20. Hwang YC, Jung CH, Ahn HY, Jeon WS, Jin SM, Woo JT et al. Optimal glycated albumin cutoff value to diagnose diabetes in Korean adults: a retrospective study based on the oral glucose tolerance test. Clin Chim Acta. 2014;437:1–5. https://doi.org/10.1016/j.cca.2014.06.027.

21. Pramodkumar TA, Jayashri R, Gokulakrishnan K, Velmurugan K, Pradeepa R, Anjana RM, Mohan V. Relationship of glycemic control markers – 1,5 anhydroglucitol, fructosamine, and glycated hemoglobin among Asian Indians with different degrees of glucose intolerance. Indian J Endocrinol Metab. 2016;20(5):690–695. https://doi.org/10.4103/2230-8210.

22. Barbarash OL, Voyevoda MI, Galstyan GR, Shestakova MV, Boytsov SA, Aleksandrova OYu et al. Pre-diabetes as an interdisciplinary problem: definition, risks, approaches to the diagnostics and prevention of type 2 diabetes and cardiovascular complications. Russian Journal of Cardiology. 2019;(4):83–91. (In Russ.) https://doi.org/10.15829/1560-4071-2019-4-83-91.

23. Echouffo-Tcheugui JB, Perreault L, Ji L, Dagogo-Jack S. Diagnosis and Management of Prediabetes: A Review. JAMA. 2023;329(14):1206–1216. https://doi.org/10.1001/jama.2023.4063.

24. Atallah R, Filion KB, Wakil SM, Genest J, Joseph L, Poirier P et al. Long-term effects of 4 popular diets on weight loss and cardiovascular risk factors: a systematic review of randomized controlled trials. Circ Cardiovasc Qual Outcomes. 2014;7(6):815–827. https://doi.org/10.1161/CIRCOUTCOMES.113.000723.

25. Драпкина ОМ, Самородская ИВ, Старинская МА, Ким ОТ, Неймарк АЕ. Ожирение: оценка и тактика ведения пациентов. Коллективная монография. М.: ФГБУ «НМИЦ ТПМ» Минздрава России; ООО «СилицеяПолиграф»; 2021. 174 с. Режим доступа: https://gnicpm.ru/wp-content/uploads/2020/01/e-monography_obesity.pdf.

26. Akasheva DU, Drapkina OM. Mediterranean Diet: Origin History, Main Components, Evidence of Benefits and Feasibility to Adapt to the Russian Reality. Rational Pharmacotherapy in Cardiology. 2020;16(2):307–316. (In Russ.) https://doi.org/10.20996/1819-6446-2020-04-03.

27. Trujillo-Garrido N, Santi-Cano MJ. Motivation and Limiting Factors for Adherence to Weight Loss Interventions among Patients with Obesity in Primary Care. Nutrients. 2022;14(14):2928. https://doi.org/10.3390/nu14142928.

28. Ametov AS, Demidova TYu, Mkrtumyan AM, Dudinskaya EN, Sizova EE. Challenge in modern endocrinology: search for combined treatment on the back of insulin resistance (lecture). Endocrinology: News, Opinions, Training. 2020;9(1):60–69. (In Russ.) https://doi.org/10.33029/2304-9529-2020-9-1-60-69.

29. Ametov AS, Prudnikova MA. Prolonged-release metformin – new standard of medical care in type 2 diabetes mellitus. Endocrinology: News, Opinions, Training. 2015;(1):19–26. (In Russ.) Available at: https://endocrinologyjournal.ru/ru/jarticles_endo/215.html.

30. Ametov AS, Barykina IN, Bondar IA, Vaysberg AR, Verbovaya NI, Zhukova LA et al. Adherence of patients to the metformin therapy with prolonged action (GlucophageR long) in real clinical practice in the Russian Federation. Endocrinology: News, Opinions, Training. 2017;(4):52–63. (In Russ.) https://doi.org/10.24411/2304-9529-2017-00054.

31. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. https://doi.org/10.1056/NEJMoa012512.

32. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3(11):866–875. https://doi.org/10.1016/S2213-8587(15)00291-0.

33. Samoilova IuG, Stankova AE, Matveeva MV, Vaizova OE, Podchinenova DV, Kudlay DA et al. Pharmacogenetics of glucagon-like peptide-1 agonists in the treatment of type 2 diabetes mellitus. Profilakticheskaya Meditsina. 2023;26(12):95–100. (In Russ.) https://doi.org/10.17116/profmed20232612195.

34. Salamah HM, Marey A, Abugdida M, Abualkhair KA, Elshenawy S, Elhassan WAF et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2024;16(1):129. https://doi.org/10.1186/s13098-024-01371-3.

35. Mkrtumyan A, Ametov A, Demidova T, Volkova A, Dudinskaya E, Vertkin A, Vorobiev S. New Approach to Overcome Insulin Resistance in Patients with Impaired Glucose Tolerance: The Results of a Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Efficacy and Safety of Subetta. J Clin Med. 2022;11(5):1390. https://doi.org/10.3390/jcm11051390.

36. Zhukova LA, Andreeva NS, Savelyeva ZhV. Evaluation of the effect of Subetta on body weight dynamics and metabolic parameters in patients with prediabetes. Endocrinology: News, Opinions, Training. 2025;14(3):22–26. (In Russ.) https://doi.org/10.33029/2304-9529-2025-14-3-22-26.

37. Zilov AV, Bolieva LZ. All-Russian observational non-interventional program on the study of the efficacy of Subetta in real-world clinical practice in patients with prediabetes (SILA). Meditsinskiy Sovet. 2025;19(6):40–47. (In Russ.) https://doi.org/10.21518/ms2025-128.